Nektar Therapeutics (NASDAQ: NKTR) said data from its ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE